title: Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma.
abstract: Malignant mesothelioma (MM) is a highly aggressive tumor associated with asbestos exposure. The identification of a marker specific for MM may be of considerable value for the early detection of this tumor and may be used in particular to screen groups with a history of asbestos exposure. The aim of this study was to evaluate serum soluble mesothelin-related peptide (SMRP) levels as a diagnostic marker for MM and investigate whether its diagnostic value is enhanced by combination with other biomarkers. Serum SMRP levels were measured using a quantitative enzyme-linked immunosorbent assay in 96 patients with MM, 55 patients with lung cancer and 39 individuals with a history of asbestos exposure. Receiver operating characteristic curves were constructed for performance evaluation. Stepwise logistic regression analysis was used to select marker combinations (MCs). Serum SMRP levels in patients with MM were significantly higher compared to those in the other groups (P<0.001). The sensitivity of SMRP levels in diagnosing MM was 56% and its specificity for MM vs. lung cancer and individuals with asbestos exposure was 87 and 92%, respectively. The area under the curve (AUC) was 0.76 [95% confidence interval (CI): 0.68-0.83] for the differentiation between MM and lung cancer and 0.78 (95% CI: 0.71-0.86) for the differentiation between MM and individuals with asbestos exposure. For the MC of presence of effusion, SMRP and carcinoembryonic antigen (CEA) levels, the AUC for the differentiation between MM and lung cancer (0.92; 95% CI: 0.88-0.97) and the differentiation between MM and individuals with asbestos exposure (0.93; 95% CI: 0.87-1.0) was significantly higher compared to that for SMRP alone (P=0.0001 and 0.0058, respectively). While the specificity of this MC was comparable to SMRP alone, its sensitivity was ∼20% higher compared to that of SMRP alone. Therefore, combining SMRP and CEA improves the diagnostic performance of SMRP alone. A combination of serum biomarkers, including SMRP, may facilitate the non-invasive diagnosis of MM.
authors.affiliation: Cancer Center, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501; ; Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501;
authors.forename: Kazuya
authors.initials: K
authors.lastname: Fukuoka
authors.affiliation: Department of Respiratory Medicine, Murakami Memorial Hospital, Asahi University, Gifu, Gifu 500-8523, Japan.
authors.forename: Kozo
authors.initials: K
authors.lastname: Kuribayashi
authors.affiliation: Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501;
authors.forename: Shusai
authors.initials: S
authors.lastname: Yamada
authors.affiliation: Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501;
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Tamura
authors.affiliation: Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501;
authors.forename: Chiharu
authors.initials: C
authors.lastname: Tabata
authors.affiliation: Cancer Center, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501; ; Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501;
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakano
keywords: Mesomark™; malignant mesothelioma; marker combinations; mesothelin; soluble mesothelin-related peptide